Cancer Research Journal

Special Issue

Immunoregulatory Functional and Therapeutic Potential of the Immune Checkpoint Blockade and Staus of Tregs & T Memory in Response to Anti-Cancer Drugs

  • Submission Deadline: Dec. 06, 2022
  • Status: Submission Closed
  • Lead Guest Editor: Samiullah Malik
About This Special Issue
Immune checkpoint blockade includes the targeted antagonism of immunosuppressive interaction between Antigen-presenting cells, cancer cells, and effector T cells. As an example here, we will consider NRP-1 as our new target because there are several studies in which it has been used as an anticancer drug. After all, in normal tissues, the expression level of NRP-1 is low. In contrast, in the case of tumors, such as glioma, pancreatic cancer, acute myeloid leukemia, as well as gastric, lung (non-small cell), colon, skin, and breast cancer, the expression level of NRP-1 is prominently increased, which has already been reported in several studies. According to the previous studies, the importance of NRP-1 gene expression in the occurrence, development, growth, and metastasis of a tumor could. It may be helpful in the effect of novel anti-cancer therapies. Neuropilin-1 was first thought to be a co-receptor of a nerve growth factor SEMA3 that combines with plexin3 and regulates synaptic growth. Subsequent investigations have shown that NRP-1 can serve as a multifunctional receptor and bind to cytokine receptors such as VEGF, TGF-β, HGF, PIGF, and PDGF. Their combinations involve cytokine signal transduction pathways, regulating the proliferation, migration, and apoptosis of endothelial and tumor cells. While several blocking and inhibiting NRP’s have been introduced in recent years to inhibit cancer proliferation and metastasis, such as monoclonal antibodies and inhibitors.
The special issue aims to explore different Immune Check point Inhibitor or blockers, which can be a potential blocker. For example, NRP-1 blocker and PD-1 blocker may have a synergy effect against cancer or find a good combination therapy against cancer.Blockade of neuropilin1 was done to inhibit the angiogenesis, which forestalls the ligation of inhibitory anti-NRP1 co-receptor to VEGF to inhibit cancer proliferation.

Keywords:

  1. Immune Checkpoint Blockade
  2. Neuropilin-1
  3. Targeted Molecular Therapy
  4. Immune Response
  5. Anti-cancer Drugs Development
  6. T Cells, Tregs and T Memory
  7. Monoclonal Antibodies
  8. Drug Combination
  9. Immune Check Point Inhibitors
Lead Guest Editor
  • Samiullah Malik

    Department of Immunology, School of Basic Medicine Shenzhen Univesity, Shenzhen, China